Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05138575 · ClinicalTrials.gov registry record · Phase 2
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
A Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT05138575 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 53 participants, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05138575, a Phase 2 study of Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Conditions Studied
Interventions
- DRUG Empagliflozin + Potassium Chloride
- DRUG Empagliflozin + Potassium Nitrate
- DRUG Potassium Chloride + Placebo for Empagliflozin
Study Locations (1)
Pennsylvania
- University of Pennsylvania Health System - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05138575
The ClinicalTrials.gov registry entry for NCT05138575 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 3 interventions - of which Empagliflozin + Potassium Chloride is the first listed.
NCT05138575 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05138575 about?
NCT05138575 is a clinical study titled "SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial". This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance ...
What is the current status of trial NCT05138575?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2022-01-24. Estimated completion is 2026-03-01.
What conditions does trial NCT05138575 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT05138575?
The interventions under investigation include: Empagliflozin + Potassium Chloride (DRUG), Empagliflozin + Potassium Nitrate (DRUG), Potassium Chloride + Placebo for Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT05138575?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05138575 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Matching Perfusion and Metabolic Activity in HFpEF
RECRUITING · Phase 2
-
Study of JK07 in Patients With Chronic Heart Failure
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
RECRUITING · Phase 2
-
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction
ACTIVE NOT RECRUITING · Phase 2
-
Cilostazol for HFpEF
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.